Neuromyelitis Optica Spectrum Disorder

There is an unmet need to differentiate NMOSD from MS due to the potential effects and safety risks associated with executing the wrong treatment regimen. Infrared spectroscopy coupled with a machine learning algorithm may be a promising point-of-care diagnostic tool. Establishing a diagnosis of neuromyelitis optica spectrum disorder (NMOSD) differentiated from multiple sclerosis (MS) is...

Multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), and myelin oligodendrocyte glycoprotein antibody (MOG-Ab)-associated disease (MOGAD) present with overlapping features, which can make a differential diagnosis difficult. Brain and spinal cord magnetic resonance imaging (MRI) is an appropriate method for determining a correct diagnosis. The overlapping clinical features of multiple sclerosis (MS), neuromyelitis optica spectrum...

Calls for parity in clinical trial enrollment among all racial groups, especially Blacks and Hispanics, are being advocated. Considering the aggressive progression of disease in racial and ethnic groups, more drug research is needed in racial groups who may be at higher risk of complications than others. Neuromyelitis optica spectrum disorder (NMOSD) is a progressive,...

Limited studies have been conducted on the long-term course of neuromyelitis optica spectrum disorder (NMOSD). However, one study sought to examine the effect of sociodemographic and illness-related factors on disease progression five years after the onset of illness. Neuromyelitis optica spectrum disorder (NMOSD) is a progressive, autoimmune disease that attacks the central nervous system, causing...

Patients with neuromyelitis optica spectrum disorder (NMOSD) may be prone to experiencing worse COVID-19 outcomes. As an autoimmune disease, NMOSD is detrimental to the optic nerve and central nervous system. Patients with NMOSD may experience disease onset at a later age, have comorbidities, and often be treated with immunosuppressive therapy, such as rituximab, azathioprine, mycophenolate...

Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune condition that affects the central nervous system and can be particularly dangerous in pregnant women. The effects of NMOSD can be harmful to both the mother and the fetus, with an increased risk of relapse and disability. While immunosuppressive therapy is the cornerstone of treatment for pregnant...

Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune disorder that manifests as inflammation of the optic nerves and central nervous system. Cases of NMOSD can typically be diagnosed with an antibody test for myelin oligodendrocyte glycoprotein (MOG) or aquaporin-4 (AQP4). Most cases are AQP4 antibody–seropositive NMOSD, with a mean age of onset of 40 years...

The prevalence of neuromyelitis optica spectrum disorder (NMOSD) is higher in racial minority groups than in white populations, with varying disease manifestations and severity. Moreover, limited data suggest that NMOSD has an earlier age of onset and tends to have worse outcomes in racial minorities. This retrospective study, published in Neurology, sought to address doubts and...

Neuromyelitis optica spectrum disorder (NMOSD) disproportionately affects Black and Hispanic/Latino individuals. Black individuals face a higher risk of developing NMOSD and an increased associated mortality from NMOSD. Moreover, Black and Hispanic/Latino individuals face greater disease severity and faster disease progression than white individuals. Researchers at the Keck School of Medicine at the University of Southern...